CTOs on the Move

Aimmune

www.aimmune.com

 
Aimmune Therapeutics, Inc. is a biopharmaceutical company that aspires to become the global leader in developing curative therapies and solutions for patients with food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies. The Company`s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.aimmune.com
  • 8000 Marina Boulevard Suite 200
    Brisbane, CA USA 94005
  • Phone: 650.614.5220

Executives

Name Title Contact Details
Narinder Singh
 Executive Vice President of Technical Operations Profile

Funding

Aimmune raised $80M on 11/04/2016
Aimmune raised $200M on 02/05/2020

Similar Companies

PAR Management

PAR Management is a Newton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biochrom

Biochrom is a Holliston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neumora Therapeutics

Brain diseases collectively represent one of the greatest challenges of our generation, affecting upwards of 1.5 billion people. However, treatments for many of the most prevalent brain disorders have been dominated by a single class of drugs, such as serotonin targeting antidepressants for MDD, leaving patients with a high degree of unmet medical need given the lack of diverse treatment options and mechanisms of action. We are taking a fundamentally different approach to the way treatments for brain diseases are developed. Our pipeline is comprised of programs pursuing therapeutically relevant targets implicated in Central Nervous System (CNS) diseases, each targeting a novel mechanism of action with best-in-class pharmacology. Our work is supported by our Precision Toolbox, which integrates a suite of translational, clinical, and computational tools to generate insights that can enable precision medicine approaches. Neumora is relentless in its commitment to discovering, developing and commercializing novel therapies for the 1.5 billion people living with brain diseases.

NuProbe

NuProbe brings together cutting-edge innovations in molecular engineering with leading scientific expertise and management to take on one of the world`s greatest challenges — non-invasive early detection of rare genetic variants in patients. NuProbe will take a multi-platform approach to apply these breakthrough technology capabilities in precision medicine to cancer diagnostics, NIPT, and infectious disease screening, building on scientific findings licensed by Wyss Institute, Harvard University.

Vanessa

Vanessa is a Rockland, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.